| Evaluation of CA19-9 as a tumor marker in urothelial malignancy. | |
| | |
MedLine Citation:
|
PMID: 15764245 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Carbohydrate antigen 19-9 (CA19-9) is known to be a marker with a high positive rate in pancreatic cancer. There are limited data on the use of CA19-9 as a tumor marker in bladder carcinoma. We tested the expression of CA19-9 in transitional cell carcinoma (TCC) cell lines and bladder cancer patients to determine its usefulness in clinical applications. MATERIAL AND METHODS: The expression of CA19-9 was determined in six TCC cell lines and 42 bladder carcinoma tissues using two approaches: immunohistochemistry and enzyme immunoassay (EIA) analysis. EIA was used for testing CA19-9 levels in spent medium of cultured TCC cells and the urine of bladder tumor patients. RESULTS: The CA19-9 value was low in spent media of the MGH-U1, MGH-U1R and MGH-U3 cell lines, but high in that of reactivity in MGH-U4 cells, while negative reactivity was found in high-grade MGH-U1 and MGH-U1R cells, both of which were derived from a stage B, grade 3 TCC. High incidences of negative CA19-9 staining were found in high-grade and invasive tumor tissues: 69.6% (16/23) and 70.8% (17/24), respectively. The sensitivity and specificity of urinary CA19-9 for detecting tumor recurrence were 83.3% and 50.8%, respectively. However, urinary tract infection also resulted in a high false-positive rate. CONCLUSION: CA19-9 is promising for use as a biomarker for the detection and monitoring of low-grade and low-stage bladder cancer, with the proviso that patients to be tested should be free of infection. |
| | |
Authors:
|
Cheng-Keng Chuang; Shuen-Kuei Liao |
Related Documents
:
|
16979735 - Clinical model of lifetime cost of treating bladder cancer and associated complications. 6159335 - Bladder neck dysfunction: the effect of the alpha-adrenergic blocking agent phentolamin... 8944065 - Incidence of recurrent bladder cancer in patients requiring admission for abdominal pai... 22161815 - The epigenetic promise for prostate cancer diagnosis. 22412135 - Evidence-based treatment of anxiety in patients with cancer. 23447365 - Circulating tumor cells in pancreatic cancer patients: methods of detection and clinica... |
Publication Detail:
|
Type: Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Scandinavian journal of urology and nephrology Volume: 38 ISSN: 0036-5599 ISO Abbreviation: Scand. J. Urol. Nephrol. Publication Date: 2004 |
Date Detail:
|
Created Date: 2005-03-18 Completed Date: 2005-04-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0114501 Medline TA: Scand J Urol Nephrol Country: Sweden |
Other Details:
|
Languages: eng Pagination: 359-65 Citation Subset: IM |
Affiliation:
|
Division of Uro-oncology, Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. chuang89@cgmh.org.tw |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biopsy, Needle CA-19-9 Antigen / genetics* Carcinoma, Transitional Cell / genetics*, pathology* Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Prognosis Sampling Studies Sensitivity and Specificity Tumor Cells, Cultured Tumor Markers, Biological / analysis* Urinary Bladder Neoplasms / genetics*, pathology Urothelium / cytology, pathology |
| Chemical | |
Reg. No./Substance:
|
0/CA-19-9 Antigen; 0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association between age, gender and reasons for smoking cessation.
Next Document: Novel prophylactic effect of doxifluridine in superficial bladder cancer.